CA2666564A1 - Formulations pour le traitement de troubles des tissus adipeux, cutanes et musculaires - Google Patents

Formulations pour le traitement de troubles des tissus adipeux, cutanes et musculaires Download PDF

Info

Publication number: CA2666564A1
Authority: CA; Canada
Prior art keywords: beta; effective amount; therapeutically effective; compound; beta adrenergic
Prior art date: 2006-10-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002666564A

Other languages

English (en)

Inventor

John Daniel Dobak

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Lithera Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-17

Filing date

2007-10-16

Publication date

2008-06-05

2007-10-16 Application filed by Individual filed Critical Individual

2008-06-05 Publication of CA2666564A1 publication Critical patent/CA2666564A1/fr

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 160
238000009472 formulation Methods 0.000 title abstract description 71
230000003387 muscular Effects 0.000 title abstract description 3
210000000577 adipose tissue Anatomy 0.000 title description 68
238000011282 treatment Methods 0.000 title description 45
210000001519 tissue Anatomy 0.000 title description 34
150000001875 compounds Chemical class 0.000 claims abstract description 110
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims abstract description 88
229960002848 formoterol Drugs 0.000 claims abstract description 86
238000013268 sustained release Methods 0.000 claims abstract description 84
239000012730 sustained-release form Substances 0.000 claims abstract description 77
238000000586 desensitisation Methods 0.000 claims abstract description 66
238000000034 method Methods 0.000 claims abstract description 65
102000012740 beta Adrenergic Receptors Human genes 0.000 claims abstract description 57
108010079452 beta Adrenergic Receptors Proteins 0.000 claims abstract description 57
239000011859 microparticle Substances 0.000 claims abstract description 45
239000003862 glucocorticoid Substances 0.000 claims abstract description 44
102000016966 beta-2 Adrenergic Receptors Human genes 0.000 claims abstract description 28
108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims abstract description 28
230000002500 effect on skin Effects 0.000 claims abstract description 12
239000000808 adrenergic beta-agonist Substances 0.000 claims description 96
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 74
229960004017 salmeterol Drugs 0.000 claims description 69
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 66
229960004436 budesonide Drugs 0.000 claims description 65
239000008194 pharmaceutical composition Substances 0.000 claims description 49
238000002347 injection Methods 0.000 claims description 47
239000007924 injection Substances 0.000 claims description 47
239000000725 suspension Substances 0.000 claims description 33
ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 25
229960004958 ketotifen Drugs 0.000 claims description 25
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 19
108060003345 Adrenergic Receptor Proteins 0.000 claims description 16
102000017910 Adrenergic receptor Human genes 0.000 claims description 16
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 15
230000001965 increasing effect Effects 0.000 claims description 15
229940039009 isoproterenol Drugs 0.000 claims description 15
238000007443 liposuction Methods 0.000 claims description 14
229960004584 methylprednisolone Drugs 0.000 claims description 13
229960000289 fluticasone propionate Drugs 0.000 claims description 12
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 12
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 9
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 9
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 9
239000000739 antihistaminic agent Substances 0.000 claims description 8
229960003957 dexamethasone Drugs 0.000 claims description 8
229960005205 prednisolone Drugs 0.000 claims description 8
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 8
229940036555 thyroid hormone Drugs 0.000 claims description 8
239000005495 thyroid hormone Substances 0.000 claims description 8
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 7
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 7
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 7
230000001387 anti-histamine Effects 0.000 claims description 7
229960002052 salbutamol Drugs 0.000 claims description 7
229960003060 bambuterol Drugs 0.000 claims description 6
ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 claims description 6
150000003943 catecholamines Chemical class 0.000 claims description 6
208000001797 obstructive sleep apnea Diseases 0.000 claims description 6
230000000699 topical effect Effects 0.000 claims description 6
LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims description 5
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims description 5
229960001022 fenoterol Drugs 0.000 claims description 5
229960003556 aminophylline Drugs 0.000 claims description 4
230000003111 delayed effect Effects 0.000 claims description 4
210000003205 muscle Anatomy 0.000 claims description 4
208000008589 Obesity Diseases 0.000 claims description 3
208000004350 Strabismus Diseases 0.000 claims description 3
238000007918 intramuscular administration Methods 0.000 claims description 3
235000020824 obesity Nutrition 0.000 claims description 3
239000000674 adrenergic antagonist Substances 0.000 claims description 2
VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 2
230000002459 sustained effect Effects 0.000 abstract description 24
239000000048 adrenergic agonist Substances 0.000 abstract description 16
229940126157 adrenergic receptor agonist Drugs 0.000 abstract description 10
230000004130 lipolysis Effects 0.000 description 63
230000000694 effects Effects 0.000 description 52
102000005962 receptors Human genes 0.000 description 51
108020003175 receptors Proteins 0.000 description 51
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 48
210000001789 adipocyte Anatomy 0.000 description 46
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 45
229940124748 beta 2 agonist Drugs 0.000 description 44
239000004480 active ingredient Substances 0.000 description 33
230000009467 reduction Effects 0.000 description 30
230000011759 adipose tissue development Effects 0.000 description 29
239000003814 drug Substances 0.000 description 29
229940079593 drug Drugs 0.000 description 28
239000004005 microsphere Substances 0.000 description 28
230000035508 accumulation Effects 0.000 description 24
238000009825 accumulation Methods 0.000 description 24
210000004027 cell Anatomy 0.000 description 23
241001465754 Metazoa Species 0.000 description 21
239000002609 medium Substances 0.000 description 21
150000003839 salts Chemical class 0.000 description 21
239000003981 vehicle Substances 0.000 description 19
206010024612 Lipoma Diseases 0.000 description 17
230000001800 adrenalinergic effect Effects 0.000 description 16
235000011187 glycerol Nutrition 0.000 description 16
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
201000010063 epididymitis Diseases 0.000 description 15
239000003795 chemical substances by application Substances 0.000 description 14
229940127212 long-acting beta 2 agonist Drugs 0.000 description 14
238000011534 incubation Methods 0.000 description 13
239000012453 solvate Substances 0.000 description 13
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 12
201000004681 Psoriasis Diseases 0.000 description 12
231100000673 dose–response relationship Toxicity 0.000 description 12
229920000642 polymer Polymers 0.000 description 12
210000003491 skin Anatomy 0.000 description 12
238000003556 assay Methods 0.000 description 11
238000013270 controlled release Methods 0.000 description 11
230000005764 inhibitory process Effects 0.000 description 11
230000000638 stimulation Effects 0.000 description 11
-1 for example Chemical class 0.000 description 10
230000002366 lipolytic effect Effects 0.000 description 10
229920001223 polyethylene glycol Polymers 0.000 description 10
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 9
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 9
230000007423 decrease Effects 0.000 description 9
239000000890 drug combination Substances 0.000 description 9
229940044601 receptor agonist Drugs 0.000 description 9
239000000018 receptor agonist Substances 0.000 description 9
239000000243 solution Substances 0.000 description 9
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 8
208000035484 Cellulite Diseases 0.000 description 8
206010049752 Peau d'orange Diseases 0.000 description 8
REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 8
230000036232 cellulite Effects 0.000 description 8
XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 8
210000002510 keratinocyte Anatomy 0.000 description 8
231100000682 maximum tolerated dose Toxicity 0.000 description 8
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 8
230000035755 proliferation Effects 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
230000004044 response Effects 0.000 description 8
238000007920 subcutaneous administration Methods 0.000 description 8
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 7
239000000556 agonist Substances 0.000 description 7
210000001367 artery Anatomy 0.000 description 7
230000015556 catabolic process Effects 0.000 description 7
239000003246 corticosteroid Substances 0.000 description 7
229940095074 cyclic amp Drugs 0.000 description 7
230000003828 downregulation Effects 0.000 description 7
229960002714 fluticasone Drugs 0.000 description 7
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 7
239000000499 gel Substances 0.000 description 7
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 7
150000002632 lipids Chemical class 0.000 description 7
238000011068 loading method Methods 0.000 description 7
238000012423 maintenance Methods 0.000 description 7
210000000229 preadipocyte Anatomy 0.000 description 7
108020001621 Natriuretic Peptide Proteins 0.000 description 6
102000004571 Natriuretic peptide Human genes 0.000 description 6
102000030621 adenylate cyclase Human genes 0.000 description 6
108060000200 adenylate cyclase Proteins 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
229920001577 copolymer Polymers 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
210000002950 fibroblast Anatomy 0.000 description 6
239000000692 natriuretic peptide Substances 0.000 description 6
229940127211 short-acting beta 2 agonist Drugs 0.000 description 6
238000007619 statistical method Methods 0.000 description 6
210000004003 subcutaneous fat Anatomy 0.000 description 6
239000000126 substance Substances 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 5
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 5
102000002723 Atrial Natriuretic Factor Human genes 0.000 description 5
101800001288 Atrial natriuretic factor Proteins 0.000 description 5
101800001890 Atrial natriuretic peptide Proteins 0.000 description 5
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 5
MGVGMXLGOKTYKP-ZFOBEOMCSA-N acetic acid;(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC(O)=O.C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 MGVGMXLGOKTYKP-ZFOBEOMCSA-N 0.000 description 5
230000004913 activation Effects 0.000 description 5
102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 5
108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 5
239000012131 assay buffer Substances 0.000 description 5
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 5
238000006731 degradation reaction Methods 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
238000013401 experimental design Methods 0.000 description 5
239000012091 fetal bovine serum Substances 0.000 description 5
229960000193 formoterol fumarate Drugs 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
230000006698 induction Effects 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
239000007788 liquid Substances 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
229960001293 methylprednisolone acetate Drugs 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
210000003800 pharynx Anatomy 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
229940042129 topical gel Drugs 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
208000029549 Muscle injury Diseases 0.000 description 4
ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 4
HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 4
206010040954 Skin wrinkling Diseases 0.000 description 4
102000000019 Sterol Esterase Human genes 0.000 description 4
108010055297 Sterol Esterase Proteins 0.000 description 4
206010043087 Tachyphylaxis Diseases 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000003243 anti-lipolytic effect Effects 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
235000011990 fisetin Nutrition 0.000 description 4
235000021588 free fatty acids Nutrition 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
239000001863 hydroxypropyl cellulose Substances 0.000 description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
210000001596 intra-abdominal fat Anatomy 0.000 description 4
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
210000001821 langerhans cell Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000005012 migration Effects 0.000 description 4
238000013508 migration Methods 0.000 description 4
229960001285 quercetin Drugs 0.000 description 4
235000005875 quercetin Nutrition 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 4
229960005018 salmeterol xinafoate Drugs 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
210000002027 skeletal muscle Anatomy 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
238000011200 topical administration Methods 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
150000003626 triacylglycerols Chemical class 0.000 description 4
230000003827 upregulation Effects 0.000 description 4
230000037303 wrinkles Effects 0.000 description 4
GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 3
102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 3
101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 3
102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 3
101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 3
206010006895 Cachexia Diseases 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 3
206010012438 Dermatitis atopic Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
241000700159 Rattus Species 0.000 description 3
238000000692 Student's t-test Methods 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
230000030741 antigen processing and presentation Effects 0.000 description 3
201000008937 atopic dermatitis Diseases 0.000 description 3
108010038640 atrial natriuretic factor receptor A Proteins 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
229960005084 calcitriol Drugs 0.000 description 3
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 3
230000037319 collagen production Effects 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
230000036541 health Effects 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
239000007972 injectable composition Substances 0.000 description 3
239000002502 liposome Substances 0.000 description 3
230000007774 longterm Effects 0.000 description 3
210000002751 lymph Anatomy 0.000 description 3
210000002752 melanocyte Anatomy 0.000 description 3
239000013642 negative control Substances 0.000 description 3
HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 3
150000005830 nonesterified fatty acids Chemical class 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
206010033675 panniculitis Diseases 0.000 description 3
239000002245 particle Substances 0.000 description 3
230000001766 physiological effect Effects 0.000 description 3
229920000747 poly(lactic acid) Polymers 0.000 description 3
230000009919 sequestration Effects 0.000 description 3
210000001584 soft palate Anatomy 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
230000001629 suppression Effects 0.000 description 3
229940037128 systemic glucocorticoids Drugs 0.000 description 3
150000003505 terpenes Chemical class 0.000 description 3
235000007586 terpenes Nutrition 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 3
239000011534 wash buffer Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
208000016261 weight loss Diseases 0.000 description 3
230000004580 weight loss Effects 0.000 description 3
UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 2
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 2
XRHGYUZYPHTUJZ-UHFFFAOYSA-M 4-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-M 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 2
108010078606 Adipokines Proteins 0.000 description 2
102000014777 Adipokines Human genes 0.000 description 2
102000003916 Arrestin Human genes 0.000 description 2
108090000328 Arrestin Proteins 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
239000000478 adipokine Substances 0.000 description 2
239000000464 adrenergic agent Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000004075 alteration Effects 0.000 description 2
229940072107 ascorbate Drugs 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000002981 blocking agent Substances 0.000 description 2
210000001217 buttock Anatomy 0.000 description 2
244000309466 calf Species 0.000 description 2
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
229960001117 clenbuterol Drugs 0.000 description 2
STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 2
229940000425 combination drug Drugs 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000009849 deactivation Effects 0.000 description 2
MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
150000004683 dihydrates Chemical class 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
238000013265 extended release Methods 0.000 description 2
210000001097 facial muscle Anatomy 0.000 description 2
229940050410 gluconate Drugs 0.000 description 2
JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
125000003827 glycol group Chemical group 0.000 description 2
239000000017 hydrogel Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 2
229960003630 ketotifen fumarate Drugs 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
UWKAYLJWKGQEPM-LBPRGKRZSA-N linalyl acetate Chemical compound CC(C)=CCC[C@](C)(C=C)OC(C)=O UWKAYLJWKGQEPM-LBPRGKRZSA-N 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
238000005259 measurement Methods 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
229940049964 oleate Drugs 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
210000003254 palate Anatomy 0.000 description 2
238000005192 partition Methods 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
230000001185 psoriatic effect Effects 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
229960001860 salicylate Drugs 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
230000011664 signaling Effects 0.000 description 2
201000002859 sleep apnea Diseases 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
229940034208 thyroxine Drugs 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
230000002792 vascular Effects 0.000 description 2
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 2
NOOLISFMXDJSKH-AEJSXWLSSA-N (+)-menthol Chemical compound CC(C)[C@H]1CC[C@H](C)C[C@@H]1O NOOLISFMXDJSKH-AEJSXWLSSA-N 0.000 description 1
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
GIIZNNXWQWCKIB-VWLOTQADSA-N (R)-salmeterol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-VWLOTQADSA-N 0.000 description 1
239000005968 1-Decanol Substances 0.000 description 1
SJJCQDRGABAVBB-UHFFFAOYSA-M 1-hydroxy-2-naphthoate Chemical compound C1=CC=C2C(O)=C(C([O-])=O)C=CC2=C1 SJJCQDRGABAVBB-UHFFFAOYSA-M 0.000 description 1
SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical class C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
102000012421 C-Type Natriuretic Peptide Human genes 0.000 description 1
101800000060 C-type natriuretic peptide Proteins 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
108010050286 Dendroaspis natriuretic peptide Proteins 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
108010078321 Guanylate Cyclase Proteins 0.000 description 1
102000014469 Guanylate cyclase Human genes 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
208000003367 Hypopigmentation Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
206010028289 Muscle atrophy Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 1
206010040925 Skin striae Diseases 0.000 description 1
208000031439 Striae Distensae Diseases 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
208000010399 Wasting Syndrome Diseases 0.000 description 1
BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
230000008484 agonism Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000001195 anabolic effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
239000000560 biocompatible material Substances 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001601 blood-air barrier Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
235000017663 capsaicin Nutrition 0.000 description 1
229960002504 capsaicin Drugs 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960005233 cineole Drugs 0.000 description 1
RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000011109 contamination Methods 0.000 description 1
208000019000 darkening of skin Diseases 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
238000013461 design Methods 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
231100000371 dose-limiting toxicity Toxicity 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000007720 emulsion polymerization reaction Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000004146 energy storage Methods 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
230000019305 fibroblast migration Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
229940021598 formoterol and budesonide Drugs 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
230000007407 health benefit Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
150000002433 hydrophilic molecules Chemical class 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000003425 hypopigmentation Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229950008325 levothyroxine Drugs 0.000 description 1
UWKAYLJWKGQEPM-UHFFFAOYSA-N linalool acetate Natural products CC(C)=CCCC(C)(C=C)OC(C)=O UWKAYLJWKGQEPM-UHFFFAOYSA-N 0.000 description 1
230000006372 lipid accumulation Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000008099 melanin synthesis Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 1
210000004249 mesenteric artery inferior Anatomy 0.000 description 1
210000001363 mesenteric artery superior Anatomy 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229950009831 methylprednisolone succinate Drugs 0.000 description 1
201000000585 muscular atrophy Diseases 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
230000009369 negative regulation of fat cell proliferation Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000007427 paired t-test Methods 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
229960001999 phentolamine Drugs 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920002721 polycyanoacrylate Polymers 0.000 description 1
229920006149 polyester-amide block copolymer Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000033300 receptor internalization Effects 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
229940021615 salmeterol and budesonide Drugs 0.000 description 1
229940021597 salmeterol and fluticasone Drugs 0.000 description 1
230000036186 satiety Effects 0.000 description 1
235000019627 satiety Nutrition 0.000 description 1
102000014452 scavenger receptors Human genes 0.000 description 1
108010078070 scavenger receptors Proteins 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000012192 staining solution Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
210000003207 subcutaneous adipocyte Anatomy 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012353 t test Methods 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
239000006200 vaporizer Substances 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
235000005282 vitamin D3 Nutrition 0.000 description 1
239000011647 vitamin D3 Substances 0.000 description 1
229940021056 vitamin d3 Drugs 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
229960000317 yohimbine Drugs 0.000 description 1
AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Obesity (AREA)
Dermatology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Zoology (AREA)
Transplantation (AREA)
Child & Adolescent Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002666564A 2006-10-17 2007-10-16 Formulations pour le traitement de troubles des tissus adipeux, cutanes et musculaires Abandoned CA2666564A1 (fr)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US85222106P	2006-10-17	2006-10-17
US60/852,221		2006-10-17
US89800907P	2007-01-29	2007-01-29
US60/898,009		2007-01-29
US91901107P	2007-03-20	2007-03-20
US60/919,011		2007-03-20
PCT/US2007/081568 WO2008067060A2 (fr)	2006-10-17	2007-10-16	Formulations pour le traitement de troubles des tissus adipeux, cutanés et musculaires

Publications (1)

Publication Number	Publication Date
CA2666564A1 true CA2666564A1 (fr)	2008-06-05

Family

ID=38701793

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CA2666612A Expired - Fee Related CA2666612C (fr)	2006-10-17	2007-09-27	Procedes, compositions, et formulations pour le traitement de la maladie de l'oeil liee a la thyroide
CA002666564A Abandoned CA2666564A1 (fr)	2006-10-17	2007-10-16	Formulations pour le traitement de troubles des tissus adipeux, cutanes et musculaires

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CA2666612A Expired - Fee Related CA2666612C (fr)	2006-10-17	2007-09-27	Procedes, compositions, et formulations pour le traitement de la maladie de l'oeil liee a la thyroide

Country Status (12)

Country	Link
US (3)	US20100119609A1 (fr)
EP (2)	EP2077830B1 (fr)
JP (5)	JP2010506941A (fr)
KR (1)	KR101068603B1 (fr)
AU (2)	AU2007313077B2 (fr)
CA (2)	CA2666612C (fr)
ES (1)	ES2398480T3 (fr)
GB (2)	GB2443287B (fr)
IL (2)	IL198183A (fr)
MX (2)	MX2009004198A (fr)
PL (1)	PL2077830T3 (fr)
WO (2)	WO2008048770A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8404750B2 (en)	2009-05-27	2013-03-26	Lithera, Inc.	Methods for administration and formulations for the treatment of regional adipose tissue
US8420625B2 (en)	2005-07-14	2013-04-16	Lithera, Inc	Lipolytic methods for regional adiposity

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2009004198A (es) *	2006-10-17	2009-10-19	Lithera Inc	Metodos, composiciones y formulaciones para el tratamiento de enfermedad ocular tiroidea.
US20110268688A1 (en) *	2008-06-25	2011-11-03	Mccarthy James Timothy	Method and compositions for improving skin and body appearance
WO2010003011A1 (fr)	2008-07-01	2010-01-07	Bruce Becker	Aiguille rétro-oculaire et procédés d'utilisation
RU2557533C2 (ru)	2009-11-06	2015-07-20	Ск Биофармасъютиклс Ко., Лтд.	Способы лечения синдрома фибромиалгии
ES2447295T3 (es)	2009-11-06	2014-03-11	Sk Biopharmaceuticals Co., Ltd.	Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
GB2477030A (en) *	2010-01-15	2011-07-20	Lithera Inc	Lyophilised forms of fluticasone, salmeterol and combinations thereof
US9320723B2 (en)	2010-05-03	2016-04-26	University Of Rochester	Methods of treating thyroid eye disease
GEP201606551B (en) *	2010-11-24	2016-10-10	Novamedica Llc	Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging
GB2485886A (en) *	2010-11-24	2012-05-30	Lithera Inc	Injectable formulations comprising a lipophilic glucocorticosteroid for regional adiposity reduction
US8765725B2 (en)	2012-05-08	2014-07-01	Aciex Therapeutics, Inc.	Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
PL3517541T3 (pl)	2012-05-08	2020-12-28	Nicox Ophthalmics, Inc.	Postać polimorficzna propionianu flutykazonu
US9694050B2 (en)	2012-10-21	2017-07-04	University Of Rochester	THY1 (CD90) as a novel therapy to control adipose tissue accumulation
US9815865B2 (en)	2013-01-07	2017-11-14	Nicox Ophthalmics, Inc.	Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
AU2014209141B2 (en)	2013-01-24	2018-05-10	Palvella Therapeutics, Inc.	Compositions for transdermal delivery of mTOR inhibitors
WO2014153541A1 (fr)	2013-03-21	2014-09-25	Eupraxia Pharmaceuticals USA LLC	Composition à libération prolongée injectable et son procédé d'utilisation pour traiter une inflammation dans des articulations et la douleur associée à celle-ci
CA2908731A1 (fr) *	2013-04-12	2014-10-16	Allergan, Inc.	Liberation prolongee de bimatoprost, et analogues de bimatoprost, prostamides et prostaglandines pour la reduction des graisses
US9351945B1 (en)	2015-02-27	2016-05-31	John Daniel Dobak, III	Reduction of adipose tissue
RU2018119121A (ru)	2015-10-27	2019-11-28	Юпраксия Фармасьютикалз Инк.	Лекарственные формы местных анастетиков с замедленным высвобождением
WO2017218284A1 (fr) *	2016-06-13	2017-12-21	Massachusetts Eye And Ear Infirmary	Thérapie orbitale locale contre la maladie de la thyroïde de l'oeil
JP7108631B2 (ja)	2017-01-06	2022-07-28	パルヴェラセラピューティクス、インク．	ｍＴＯＲ阻害剤の無水組成物およびその使用方法
US11208489B2 (en)	2018-01-24	2021-12-28	Horizon Therapeutics Ireland Dac	Methods for the treatment of thyroid eye disease
WO2019173352A1 (fr) *	2018-03-05	2019-09-12	Hznp Limited	Procédés pour le traitement de l'ophtalmopathie thyroïdienne
JP2021530463A (ja)	2018-07-02	2021-11-11	パルヴェラセラピューティクス、インク．	ｍＴＯＲ阻害剤の無水組成物および使用方法
MX2021014357A (es) *	2019-06-10	2022-02-22	Jenivision Inc	Metodos y formulaciones para tratar trastornos de la vision.
US10857213B1 (en) *	2019-08-13	2020-12-08	Standard Of Care Corporation	Hyaluronidase compositions and methods of using same to treat a cosmetic condition
US20230012731A1 (en) *	2019-11-26	2023-01-19	Standard Of Care Corporation	Hyaluronidase compositions and methods of using same to treat peri-orbital hollowness and tear through deformities
US20230302099A1 (en) *	2020-08-20	2023-09-28	Iliana E. Sweis	Hyaluronidase fusion proteins comprising a targeting sequence and methods of using same to treat a cosmetic condition
WO2025073804A1 (fr) *	2023-10-04	2025-04-10	Rheinische Friedrich-Wilhelms Universität Bonn, Körperschaft Des Öffentlichen Rechts	Composition comprenant un agoniste du récepteur bêta-2-adrénergique pour administration transdermique

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3898330A (en) *	1973-08-01	1975-08-05	Squibb & Sons Inc	Corticosteroid phosphate salts/neomycin sulfate ophthalmic
US4525359A (en) *	1982-12-10	1985-06-25	Greenway Frank L Iii	Treatment for selective weight control
NZ212204A (en) *	1984-06-04	1988-07-28	Merck & Co Inc	Growth-promoting compositions containing hydroxylic compounds
JPH0696521B2 (ja) *	1986-01-31	1994-11-30	千寿製薬株式会社	眼局所投与用眼圧降下剤
FR2602423B1 (fr) *	1986-08-08	1989-05-05	Ethypharm Sa	Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US5270305A (en) *	1989-09-08	1993-12-14	Glaxo Group Limited	Medicaments
CA2030174C (fr) *	1990-01-10	1996-12-24	Anthony H. Cincotta	Procede pour la reduction a long terme des reserves lipidiques, de l'insulinoresistance, de l'hyperinsulinemie et de l'hypoglycemie chez les vertebres
US5126147A (en) *	1990-02-08	1992-06-30	Biosearch, Inc.	Sustained release dosage form
US5919827A (en) *	1990-07-11	1999-07-06	Sepracor Inc.	Method for treating asthma using optically pure R(-) salmeterol
WO1993011773A1 (fr) *	1991-12-18	1993-06-24	Aktiebolaget Astra	Nouvelle combinaison de formoterol et de budesonide
US5314916A (en) *	1993-04-19	1994-05-24	Alcon Laboratories, Inc.	B2 adrenegic agonists and use thereof in the treatment of glaucoma
US6316443B1 (en) *	1994-08-04	2001-11-13	Merck & Co., Inc.	Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
US5855913A (en) *	1997-01-16	1999-01-05	Massachusetts Instite Of Technology	Particles incorporating surfactants for pulmonary drug delivery
GB9612297D0 (en) *	1996-06-11	1996-08-14	Minnesota Mining & Mfg	Medicinal aerosol formulations
US6066675A (en) *	1996-09-13	2000-05-23	The Regents Of The University Of California	Method for treatment of retinal diseases
JP4335316B2 (ja)	1996-09-19	2009-09-30	ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン	アルギネートまたは修飾アルギネートのようなポリサッカライドを含むポリマー
SE9700135D0 (sv) *	1997-01-20	1997-01-20	Astra Ab	New formulation
SK122199A3 (en) *	1997-03-18	2000-12-11	Basf Ag	Methods and compositions for modulating responsiveness to corticosteroids
US6656508B2 (en) *	1997-04-17	2003-12-02	Amgen Inc.	Sustained-release alginate gels
BR9815470A (pt)	1997-04-30	2001-10-23	Bridge Pharma Inc	Composição e processo usando um eutÈmero
US20010044584A1 (en) *	1997-08-28	2001-11-22	Kensey Kenneth R.	In vivo delivery methods and compositions
SE9703407D0 (sv) *	1997-09-19	1997-09-19	Astra Ab	New use
US20030095925A1 (en) *	1997-10-01	2003-05-22	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20040152664A1 (en) *	1998-09-02	2004-08-05	Allergan, Inc.	Prednisolone compositions
US6384259B1 (en) *	1998-11-16	2002-05-07	Medimmune Oncology, Inc.	Stable amorphous amifostine compositions and dosage form
AU7127600A (en) *	1999-09-17	2001-04-17	Basf Aktiengesellschaft	Methods and compositions for modulating responsiveness to corticosteroids
WO2001041806A1 (fr) *	1999-12-07	2001-06-14	Rohto Pharmaceutical Co., Ltd.	Compositions ophtalmiques
US20040208910A1 (en) *	2000-04-26	2004-10-21	Control Delivery Systems, Inc.	Sustained release device and method for ocular delivery of adrenergic agents
GB0012260D0 (en) *	2000-05-19	2000-07-12	Astrazeneca Ab	Novel composition
AUPQ797700A0 (en) *	2000-06-06	2000-06-29	Austin Research Institute, The	Vaccine
FI20002215A0 (fi) *	2000-10-06	2000-10-06	Orion Yhtymae Oyj	Yhdistelmäpartikkelit
FI20002216A0 (fi) *	2000-10-06	2000-10-06	Orion Yhtymae Oyj	Yhdistelmäpartikkelit astman hoitoon
US6936426B2 (en) *	2000-10-06	2005-08-30	Harbor-Ucla Research And Education Institute	Detection of antibody mediated inflammatory auto-immune disorders
DE60117858T2 (de) *	2000-12-07	2006-11-30	Universiteit Utrecht Holding B.V.	Zusammensetzung zur behandlung von entzündlichen erkrankungen
WO2002060410A2 (fr) *	2001-01-30	2002-08-08	The Regents Of The University Of Michigan	Methodes d'administration locale a liberation prolongee de medicaments visant a l'ablation de tissus non desires
UA77656C2 (en) *	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20030055026A1 (en) *	2001-04-17	2003-03-20	Dey L.P.	Formoterol/steroid bronchodilating compositions and methods of use thereof
CA2445839A1 (fr) *	2001-04-30	2002-11-07	Glaxo Group Limited	Derives anti-inflammatoires d'androstane 17.beta.-carbothioate ester avec un groupe cyclique en position 17.alpha
US6726714B2 (en) *	2001-08-09	2004-04-27	Scimed Life Systems, Inc.	Stent delivery system
GB0124523D0 (en)	2001-10-12	2001-12-05	Glaxo Group Ltd	Pharmaceutical combination
EP1438019A1 (fr) *	2001-10-24	2004-07-21	PARI GmbH Spezialisten für effektive Inhalation	Trousse de preparation de composition pharmaceutique
US6625078B2 (en) *	2002-02-11	2003-09-23	United Memories, Inc.	Look-ahead refresh for an integrated circuit memory
ATE418347T1 (de) *	2002-02-19	2009-01-15	Resolution Chemicals Ltd	Auf lösungsmitteln basierende sterilisation von steroiden
US20050009798A1 (en) *	2002-02-20	2005-01-13	Sepracor Inc.	Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
US6643212B1 (en) *	2002-04-18	2003-11-04	United Memories, Inc.	Simultaneous function dynamic random access memory device technique
US20040028545A1 (en) *	2002-08-06	2004-02-12	Ta-Chin Wang	Cylinder assembly for a mini air compressor
AU2003263717A1 (en)	2002-09-25	2004-04-19	Astrazeneca Ab	A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US20040208833A1 (en) *	2003-02-04	2004-10-21	Elan Pharma International Ltd.	Novel fluticasone formulations
EP1613266A4 (fr) *	2003-04-15	2009-05-06	Theraquest Biosciences Llc	Methodes de traitement de la douleur et compositions associees
US9808471B2 (en) *	2003-04-16	2017-11-07	Mylan Specialty Lp	Nasal pharmaceutical formulations and methods of using the same
WO2004103057A2 (fr) *	2003-05-15	2004-12-02	The University Of Georgia Research Foundation, Inc.	Compositions et procedes permettant d'induire la mort cellulaire de tissus adipeux
SE0302029D0 (sv) *	2003-07-07	2003-07-07	Astrazeneca Ab	Novel process
TWI359675B (en) *	2003-07-10	2012-03-11	Dey L P	Bronchodilating β-agonist compositions
GB0316290D0 (en) *	2003-07-11	2003-08-13	Glaxo Group Ltd	Novel compounds
WO2005009375A2 (fr) *	2003-07-22	2005-02-03	Baxter International Inc.	Petites particules spheriques de molecules organiques de faible poids moleculaire et procedes de preparation et d'utilisation correspondants
US20050069291A1 (en) *	2003-09-25	2005-03-31	Voss James S.	Systems and methods for locating a video file
CA2533887A1 (fr) *	2003-09-30	2005-04-14	Acusphere, Inc.	Formulations pharmaceutiques a effet prolonge, administrees par injection, par voie orale ou topique
DE10347994A1 (de) *	2003-10-15	2005-06-16	Pari GmbH Spezialisten für effektive Inhalation	Wässrige Aerosol-Zubereitung
ATE551339T1 (de) *	2003-11-05	2012-04-15	Sarcode Bioscience Inc	Modulatoren der zellulären adhäsion
ES2381672T3 (es) *	2003-11-14	2012-05-30	Senju Pharmaceutical Co., Ltd.	Preparación en solución acuosa que comprende un antibiótico aminoglicósido y bromfenaco
NZ547178A (en)	2003-11-20	2008-06-30	Alteragon Pty Ltd	Method of decreasing fat deposits and body weight in mammals and birdsusing the R-isomer of Salbutamol
KR100573828B1 (ko) *	2003-12-29	2006-04-26	주식회사 하이닉스반도체	셀데이터의 손실을 방지하기 위한 반도체 메모리 소자
US20050212152A1 (en) *	2004-03-23	2005-09-29	Reens Daniel J	System and method for humidifying homes and commercial sites
EP1753445A4 (fr)	2004-05-06	2009-05-20	Molichem Medicines Inc	Traitement de maladies et de troubles oculaires utilisant des compositions lantibiotiques
US7754230B2 (en) *	2004-05-19	2010-07-13	The Regents Of The University Of California	Methods and related compositions for reduction of fat
EP1778638A1 (fr) *	2004-07-21	2007-05-02	Theravance, Inc.	Agonistes des recepteurs beta2 adrenergiques derives d'ethers de diaryle
KR20070104645A (ko) *	2005-02-18	2007-10-26	산텐 세이야꾸 가부시키가이샤	스테로이드 화합물의 부작용 경감 또는 회피 방법
WO2006108176A2 (fr) *	2005-04-08	2006-10-12	The Regents Of The University Of California	Agonistes et antagonistes du recepteur beta 2 adrenergique et modulation de cicatrisation
US7931909B2 (en) *	2005-05-10	2011-04-26	Allergan, Inc.	Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
BRPI0613034A8 (pt) *	2005-07-14	2018-01-02	Lipothera Inc	formulação injetável para acúmulo de tecido adiposo, formulação injetável e método para o tratamento de acúmulo de gordura, e, método para reduzir o tecido adiposo.
FR2893845B1 (fr) *	2005-11-30	2010-10-29	Galderma Sa	Composition sous forme de spray comprenant un corticoide et une phase huileuse
CA2631493A1 (fr) *	2005-12-15	2007-06-21	Acusphere, Inc.	Procedes d'elaboration de preparations pharmaceutiques a base de particules pour administration pulmonaire ou nasale
US20070178051A1 (en) *	2006-01-27	2007-08-02	Elan Pharma International, Ltd.	Sterilized nanoparticulate glucocorticosteroid formulations
MX2009004198A (es) *	2006-10-17	2009-10-19	Lithera Inc	Metodos, composiciones y formulaciones para el tratamiento de enfermedad ocular tiroidea.
CA2680329A1 (fr) *	2007-04-04	2008-10-16	Theratechnologies Inc.	Formulations pharmaceutiques de molecules ghrh
US20090143343A1 (en) *	2007-11-13	2009-06-04	Meritage Pharma, Inc.	Compositions for the treatment of inflammation of the gastrointestinal tract
AU2008331928B2 (en) *	2007-12-03	2012-08-16	Bridge Pharma, Inc.	Use of RR/SR-ractopamine
US9132084B2 (en) *	2009-05-27	2015-09-15	Neothetics, Inc.	Methods for administration and formulations for the treatment of regional adipose tissue
GB2477030A (en) *	2010-01-15	2011-07-20	Lithera Inc	Lyophilised forms of fluticasone, salmeterol and combinations thereof
GEP201606551B (en) *	2010-11-24	2016-10-10	Novamedica Llc	Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging

2007
- 2007-09-27 MX MX2009004198A patent/MX2009004198A/es active IP Right Grant
- 2007-09-27 JP JP2009533423A patent/JP2010506941A/ja active Pending
- 2007-09-27 CA CA2666612A patent/CA2666612C/fr not_active Expired - Fee Related
- 2007-09-27 EP EP07843370A patent/EP2077830B1/fr not_active Not-in-force
- 2007-09-27 GB GB0718905A patent/GB2443287B/en active Active
- 2007-09-27 ES ES07843370T patent/ES2398480T3/es active Active
- 2007-09-27 WO PCT/US2007/079740 patent/WO2008048770A1/fr not_active Ceased
- 2007-09-27 PL PL07843370T patent/PL2077830T3/pl unknown
- 2007-09-27 AU AU2007313077A patent/AU2007313077B2/en not_active Ceased
- 2007-09-27 US US12/445,570 patent/US20100119609A1/en not_active Abandoned
- 2007-10-16 AU AU2007325523A patent/AU2007325523A1/en not_active Abandoned
- 2007-10-16 CA CA002666564A patent/CA2666564A1/fr not_active Abandoned
- 2007-10-16 WO PCT/US2007/081568 patent/WO2008067060A2/fr not_active Ceased
- 2007-10-16 US US12/445,571 patent/US20100137267A1/en not_active Abandoned
- 2007-10-16 KR KR1020097009974A patent/KR101068603B1/ko not_active Expired - Fee Related
- 2007-10-16 GB GB0804401A patent/GB2453188B/en not_active Expired - Fee Related
- 2007-10-16 MX MX2009004199A patent/MX2009004199A/es not_active Application Discontinuation
- 2007-10-16 EP EP07871172A patent/EP2076269A4/fr not_active Withdrawn
2009
- 2009-04-16 IL IL198183A patent/IL198183A/en not_active IP Right Cessation
- 2009-04-16 IL IL198184A patent/IL198184A/en active IP Right Grant
- 2009-10-09 JP JP2009234928A patent/JP2010006837A/ja active Pending
2012
- 2012-04-19 JP JP2012095792A patent/JP2012144565A/ja active Pending
2015
- 2015-03-24 JP JP2015060876A patent/JP2015155423A/ja active Pending
- 2015-03-24 JP JP2015060875A patent/JP2015163612A/ja active Pending
2016
- 2016-04-04 US US15/090,479 patent/US20160287611A1/en not_active Abandoned

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8420625B2 (en)	2005-07-14	2013-04-16	Lithera, Inc	Lipolytic methods for regional adiposity
US9370498B2 (en)	2005-07-14	2016-06-21	Neothetics, Inc.	Methods of using lipolytic formulations for regional adipose tissue treatment
US9452147B2 (en)	2005-07-14	2016-09-27	Neothetics, Inc.	Lipolytic methods
US9707192B2 (en)	2005-07-14	2017-07-18	Neothetics, Inc.	Lipolytic methods
US8404750B2 (en)	2009-05-27	2013-03-26	Lithera, Inc.	Methods for administration and formulations for the treatment of regional adipose tissue
US9132084B2 (en)	2009-05-27	2015-09-15	Neothetics, Inc.	Methods for administration and formulations for the treatment of regional adipose tissue
US9452132B2 (en)	2009-05-27	2016-09-27	Neothetics, Inc.	Methods for administration and formulations for the treatment of regional adipose tissue

Also Published As

Publication number	Publication date
CA2666612A1 (fr)	2008-04-24
MX2009004198A (es)	2009-10-19
EP2077830A4 (fr)	2010-04-14
GB0718905D0 (en)	2007-11-07
AU2007313077A1 (en)	2008-04-24
JP2015163612A (ja)	2015-09-10
IL198183A (en)	2013-09-30
JP2010506941A (ja)	2010-03-04
IL198184A0 (en)	2009-12-24
AU2007325523A1 (en)	2008-06-05
WO2008067060A8 (fr)	2008-12-31
PL2077830T3 (pl)	2013-04-30
KR101068603B1 (ko)	2011-09-30
JP2010006837A (ja)	2010-01-14
JP2012144565A (ja)	2012-08-02
GB2443287A (en)	2008-04-30
GB0804401D0 (en)	2008-04-16
US20160287611A1 (en)	2016-10-06
IL198183A0 (en)	2009-12-24
EP2076269A4 (fr)	2010-05-19
MX2009004199A (es)	2009-09-16
IL198184A (en)	2015-06-30
AU2007313077B2 (en)	2011-06-02
EP2076269A2 (fr)	2009-07-08
WO2008067060A2 (fr)	2008-06-05
WO2008067060A3 (fr)	2008-08-14
ES2398480T3 (es)	2013-03-19
GB2453188A (en)	2009-04-01
EP2077830A1 (fr)	2009-07-15
GB2453188B (en)	2010-03-31
EP2077830B1 (fr)	2012-11-07
WO2008048770A1 (fr)	2008-04-24
JP2015155423A (ja)	2015-08-27
US20100137267A1 (en)	2010-06-03
CA2666612C (fr)	2012-11-27
GB2443287B (en)	2009-05-27
US20100119609A1 (en)	2010-05-13
KR20090086409A (ko)	2009-08-12

Publication	Publication Date	Title
US20100137267A1 (en)	2010-06-03	Formulations for treatment of adipose tissue, cutaneous tissue and disorders, and muscular tissue
US8420625B2 (en)	2013-04-16	Lipolytic methods for regional adiposity
JP2009501719A5 (fr)	2010-12-24
CN102448467A (zh)	2012-05-09	治疗局部脂肪组织的给药方法和制剂
CN101594873A (zh)	2009-12-02	用于治疗脂肪组织，皮肤组织和病症，和肌肉组织的配方
RU2420317C2 (ru)	2011-06-10	Препараты для лечения жировой ткани, кожной ткани и расстройств, и мышечной ткани
KR101201619B1 (ko)	2012-11-15	갑상선 안질환의 치료를 위한 방법, 조성물 및 제제
RU2431501C2 (ru)	2011-10-20	Липолитические составы с пролонгированным высвобождением для локального лечения отложения жировых тканей
MX2008000570A (es)	2008-09-26	Formulacion lipolitica mejorada de liberacion sostenida para tratamiento regional de tejido adiposo
HK1161033A (en)	2012-08-24	Sustained release enhanced lipolytic formulation for regional adipose tissue treatment

Legal Events

Date	Code	Title	Description
2009-04-16	EEER	Examination request
2012-04-19	FZDE	Discontinued